Literature DB >> 6743464

Alterations in prednisolone disposition as a result of oral contraceptive use and dose.

P J Meffin, L M Wing, B C Sallustio, P M Brooks.   

Abstract

The disposition of total and free prednisolone has been studied in eight female subjects who used combined oestrogen-progestogen oral contraceptives and in eight female subjects who did not, each of whom received separate intravenous doses of 0.1 mg/kg (low) and 1.0 mg/kg (high) of prednisolone. Mean free prednisolone clearance was reduced congruent to 30% in oral contraceptive users compared to control subjects (P less than 0.001), the difference being greater for the low dose (39%) than for the high dose (24%). Pre-dose plasma cortisol concentrations were elevated two-fold (P less than 0.001) in oral contraceptive users compared to control subjects. These effects are consistent with a mechanism in which the competitive inhibition of free prednisolone clearance by cortisol contributes to the reduction of free prednisolone clearance by oral contraceptive use. Mean total prednisolone clearance and steady state distribution volume showed an approximate two-fold dose dependent increase consistent with a similar increase in plasma prednisolone free fraction (P less than 0.001). Free prednisolone clearance showed an 18% dose dependent decrease (P less than 0.001) but free steady-state distribution volume did not change with dose. At plasma prednisolone concentrations less than 400 ng/ml, prednisolone free fractions at any prednisolone concentration were greater after the low, than after the high dose. This effect is consistent with the displacement of prednisolone by cortisol from transcortin but not from albumin.

Entities:  

Keywords:  Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Methods--side effects; Drugs--administraction and dosage; Family Planning; Oral Contraceptives--side effects; Treatment

Mesh:

Substances:

Year:  1984        PMID: 6743464      PMCID: PMC1463433          DOI: 10.1111/j.1365-2125.1984.tb02400.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects.

Authors:  M Kozower; L Veatch; M M Kaplan
Journal:  J Clin Endocrinol Metab       Date:  1974-03       Impact factor: 5.958

2.  Biologically active cortisol in plasma of oestrogen-treated and normal subjects.

Authors:  C W Burke
Journal:  Br Med J       Date:  1969-06-28

3.  Free fraction change with differing volume ratios in equilibrium dialysis: cases of non-linear drug-protein binding.

Authors:  H L Behm; J G Wagner
Journal:  J Pharm Pharmacol       Date:  1981-05       Impact factor: 3.765

4.  Impairment of diazepam metabolism by low-dose estrogen-containing oral-contraceptive steroids.

Authors:  D R Abernethy; D J Greenblatt; M Divoll; R Arendt; H R Ochs; R I Shader
Journal:  N Engl J Med       Date:  1982-04-01       Impact factor: 91.245

Review 5.  Free cortisol in human plasma.

Authors:  T G Brien
Journal:  Horm Metab Res       Date:  1980-12       Impact factor: 2.936

Review 6.  Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review.

Authors:  J G Gambertoglio; W J Amend; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1980-02

7.  Dose dependent pharmacokinetics of prednisone and prednisolone in man.

Authors:  J Q Rose; A M Yurchak; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

8.  Effects of administration of estrogen or diphenylhydantoin on the kinetics of diphenylhydantoin in man.

Authors:  J A Fernandez-Pol; A A Zaninovich
Journal:  J Nucl Med       Date:  1975-04       Impact factor: 10.057

9.  Disposition of chlordiazepoxide: sex differences and effects of oral contraceptives.

Authors:  R K Roberts; P V Desmond; G R Wilkinson; S Schenker
Journal:  Clin Pharmacol Ther       Date:  1979-06       Impact factor: 6.875

10.  Impaired elimination of caffeine by oral contraceptive steroids.

Authors:  R V Patwardhan; P V Desmond; R F Johnson; S Schenker
Journal:  J Lab Clin Med       Date:  1980-04
View more
  9 in total

Review 1.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  B M Frey; F J Frey
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 2.  Pharmacokinetic drug interactions with oral contraceptives.

Authors:  D J Back; M L Orme
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

3.  Lack of impairment of fluocortolone disposition in oral contraceptive users.

Authors:  U F Legler
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

5.  Cortisol does not inhibit prednisolone clearance.

Authors:  P J Meffin; B C Sallustio; Y J Purdie; R A Robson; L M Wing; P M Brooks
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

6.  Lack of effect of oral contraceptive use on the pharmacokinetics of quinine.

Authors:  S Wanwimolruk; S Kaewvichit; O Tanthayaphinant; C Suwannarach; A Oranratnachai
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of contraceptive steroids. An update.

Authors:  G M Shenfield; J M Griffin
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

Review 8.  Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

Authors:  M Schwab; U Klotz
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 9.  Oral contraceptives. Are drug interactions of clinical significance?

Authors:  G M Shenfield
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.